Evidence map›Paper›PMID 36645384›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.

Terry Ng, Valeria Flores-Malavet, Mishfak A M Mansoor, Andrea C Arvelo, Kunal Dhume, Emily Prokop, K Kai McKinstry, Tara M Strutt

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Terry NgDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-1488-6872
Valeria Flores-MalavetDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.
Mishfak A M MansoorDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-4930-0552
Andrea C ArveloDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-4008-8997
Kunal DhumeDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.
Emily ProkopDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0001-8843-7773
K Kai McKinstryDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-5038-7229
Tara M StruttDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-4465-1783
University of Central Florida · US

Funding

Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infectionR01AI165406 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI STRUTT, TARA MARLENE · 2021 to 2025
$1.9M
Memory T cell protection of reproductive health following influenza infectionR21HD093948 · NICHD · UNIVERSITY OF CENTRAL FLORIDA · PI STRUTT, TARA MARLENE · 2018 to 2019
$410k
NIAID NIH HHS R01 AI165406NICHD NIH HHS R21 HD093948
6 · The paper itself

Abstract

Overcoming interfering impacts of pre-existing immunity to generate universally protective influenza A virus (IAV)-specific T cell immunity through vaccination is a high priority. In this study, we passively transfer varied amounts of H1N1-IAV-specific immune serum before H1N1-IAV infection to determine how different levels of pre-existing Ab influence the generation and protective potential of heterosubtypic T cell responses in a murine model. Surprisingly, IAV nucleoprotein-specific CD4 and CD8 T cell responses are readily detected in infected recipients of IAV-specific immune serum regardless of the amount transferred. When compared with responses in control groups and recipients of low and intermediate levels of convalescent serum, nucleoprotein-specific T cell responses in recipients of high levels of IAV-specific serum, which prevent overt weight loss and reduce peak viral titers in the lungs, are, however, markedly reduced. Although detectable at priming, this response recalls poorly and is unable to mediate protection against a lethal heterotypic (H3N2) virus challenge at later memory time points. A similar failure to generate protective heterosubtypic T cell immunity during IAV priming is seen in offspring of IAV-primed mothers that naturally receive high titers of IAV-specific Ab through maternal transfer. Our findings support that priming of protective heterosubtypic T cell responses can occur in the presence of intermediate levels of pre-existing Ab. These results have high relevance to vaccine approaches aiming to incorporate and evaluate cellular and humoral immunity towards IAV and other viral pathogens against which T cells can protect against variants escaping Ab-mediated protection.

Indexed as

Influenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibodies, ViralCD8-Positive T-LymphocytesHumansImmune SeraInfluenza A Virus, H3N2 SubtypeMiceAntibodies, ViralImmune SeraInfluenza Vaccines

Identifiers

PMID36645384
PMCPMC9998374
OpenAlexW4316661606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.